XML 59 R48.htm IDEA: XBRL DOCUMENT v3.26.3
Revenue - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 08, 2026
Sep. 30, 2026
Sep. 30, 2026
Nov. 03, 2025
Convertible Debt | Exact Convertible Note        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Shares upon conversion (in shares) 3,364,814      
License and collaboration revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized     $ 187.7  
License and collaboration revenue | Exact Science License Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Transaction price       $ 143.4
Regulatory milestones       700.0
Development payments       $ 20.0
Development payment satisfaction period       3 years
Variable consideration       $ 20.0
Revenue recognized   $ 182.5 187.7  
Performance obligation amount   28.6 28.6  
License and collaboration revenue | Exact Science License Agreement | Research and Development Services Performed        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Performance obligation amount   $ 21.7 $ 21.7  
License and collaboration revenue | Exact Science License Agreement | Research and Development Services Performed | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-10-01        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Performance obligation period   2 years 2 years  
License and collaboration revenue | Exact Science License Agreement | Material Right as Laboratory Tests Performed        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Performance obligation amount   $ 6.1 $ 6.1  
License and collaboration revenue | Exact Science License Agreement | Satisfaction of Technology Transfers        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Performance obligation amount   0.7 0.7  
License and collaboration revenue | Exact Science License Agreement | Regulatory Approval of Collaboration Product        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Regulatory milestones       100.0
License and collaboration revenue | Exact Science License Agreement | Regulatory Approval of Next-Generation Test        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Regulatory milestones   100.0 $ 100.0 100.0
License and collaboration revenue | Exact Science License Agreement | Collaboration Product Rating        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Regulatory milestones       500.0
License and collaboration revenue | Upfront Payments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Transaction price       75.0
License and collaboration revenue | Reimbursement for Development Costs        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Transaction price       60.0
License and collaboration revenue | Convertible Note Proceeds        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Transaction price       $ 8.4
License and collaboration revenue | Exclusive Commercialization License        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized   157.5    
License and collaboration revenue | Cumulative Catch-Up Adjustments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized   22.5    
License and collaboration revenue | Research and Development Services        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized   $ 2.5